title: MACOP-B treatment in patients with Ki-1-positive large-cell anaplastic lymphoma.
abstract: Nine adult patients with Ki-1-positive large-cell anaplastic lymphoma were treated with MACOP-B. Two suffered from relapsed disease and had previously received chemotherapy; a third patient had received a single dose of 100 mg/m2 cisplatin before initiation of MACOP-B. The stage of lymphoma was determined according to the Ann Arbor Conference criteria and was II in one, III in two and IV in six patients. All patients had constitutional symptoms. Five patients had achieved complete remission 4 weeks after termination of the protocol and there were two partial remissions. One patient died of massive pulmonary embolism during the 4th week of treatment; another patient, who had received MACOP-B as salvage therapy, died of progressive lymphoma 1 month after completion of the regimen. Maximal observed toxicities according to WHO were mucositis grade 3 (n = 3) and there were three cases with thromboembolic complications, including a fatal pulmonary embolism in a young patient. However, MACOP-B appears an effective, fairly well-tolerated and feasible therapy for patients with Ki-1-positive large-cell anaplastic lymphoma.
authors.affiliation: First Department of Medicine, University of Vienna, Austria.
authors.forename: C
authors.initials: C
authors.lastname: Marosi
authors.forename: R
authors.initials: R
authors.lastname: Heinz
authors.forename: G
authors.initials: G
authors.lastname: Steger
authors.forename: A
authors.initials: A
authors.lastname: Fortelny
authors.forename: A
authors.initials: A
authors.lastname: Chott
authors.forename: H
authors.initials: H
authors.lastname: Hanak
authors.forename: T
authors.initials: T
authors.lastname: Radaszkiewicz
authors.forename: M
authors.initials: M
authors.lastname: Baur
authors.forename: G
authors.initials: G
authors.lastname: Kreiner
authors.forename: I
authors.initials: I
authors.lastname: Schwarzinger
mesh_terms: D000328:Adult; D000368:Aged; D015703:Antigens, CD / Q000032:analysis*; D000951:Antigens, Neoplasm / Q000032:analysis*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage / Q000009:adverse effects; D001859:Bone Neoplasms / Q000188:drug therapy / Q000276:immunology; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D017730:Ki-1 Antigen; D002955:Leucovorin / Q000008:administration & dosage / Q000009:adverse effects; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy* / Q000276:immunology; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects; D012074:Remission Induction; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D015703:Antigens, CD; D000951:Antigens, Neoplasm; D017730:Ki-1 Antigen; D001761:Bleomycin; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D002955:Leucovorin; D011241:Prednisone; D008727:Methotrexate